NCT03886415View on ClinicalTrials.gov

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

January 8, 2019

Primary Completion Date

February 2, 2021

Study Completion Date

February 2, 2021

Conditions
Myelofibrosis
Interventions
DRUG

Jaktinib hydrochloride tablets

Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group

Trial Locations (1)

310003

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT03886415 - Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis. | Biotech Hunter | Biotech Hunter